Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma

NCT00024557 is registered in ClinicalTrials.gov with INSYS Therapeutics Inc as lead sponsor.

NCT NCT00024557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma
Lead sponsor
INSYS Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2001
Completion date
July 31, 2007
Enrollment
40
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme, malignant astrocytoma, malignant glioma, mixed oligoastrocytoma